Pancreatic cancer protein biomarker and application and detection chip thereof, and detection device

Abstract

The invention provides a pancreatic cancer protein biomarker and an application thereof, wherein the marker comprises CRP, ICAM-1, OPG and CA19-9 which stably exist in human serum / plasma and can be detected. The pancreatic cancer protein biomarker is obtained through screening in a way of low abundance difference research, and validation indicates that the biomarker participates in generation and development processes of pancreatic cancer, is a believable pancreatic cancer early biomarker, and has higher specificity and sensitivity compared with conventional detection markers. on the basis, the invention further provides a detection chip aiming at the pancreatic cancer protein biomarker and a detection device including the same; according to the detection chip, a specific CRP monoclonal antibody, a specific ICAM-1 monoclonal antibody, a specific OPG monoclonal antibody and a specific CA19-9 respectively prepared through immunization of the CRP, ICAM-1, OPG and CA19-9 are used as the basis and are fixed on a solid-phase matrix to form the chip; through antigen-antibody specific combination, biomarking proteins are detected, and higher accuracy and specificity are achieved.

Description

technical field [0001] The invention belongs to the technical field of biological detection, and in particular relates to a pancreatic cancer protein biomarker, its application, a detection chip and a detection device. Background technique [0002] Pancreatic cancer is a highly malignant tumor of the digestive tract that is difficult to diagnose and treat. About 90% of them are ductal adenocarcinomas originating from the ductal epithelium. Usually after the onset of patients, the 5-year survival rate is <1%, which is one of the malignant tumors with the worst prognosis. [0003] An important reason for the low prognosis and survival rate of pancreatic cancer is that pancreatic cancer has no symptoms in the early stage, and it is difficult to be detected in the latent period or early stage of pancreatic cancer, thus delaying the best treatment time. It is mainly difficult to be detected because there are no symptoms in the early stage of the disease, and the most accurate...

AI Technical Summary

Problems solved by technology

[0003] An important reason for the low prognosis and survival rate of pancreatic cancer is that pancreatic cancer has no symptoms in the early stage, and it is difficult to be detected in the latent period or early stage of pancreatic cancer, thus delaying the best treatment time

It is mainly difficult to be detected because there are no symptoms in the early stage of the disease, and the most accurate detection markers currently available for pancreatic cancer, CA19-9, CEA, and CA242, have a certain positive rate when tested, and do not high specificity

According to statistical data, the sensitivity of using the above markers in the detection of pancreatic cancer during the gestation period (before canceration) is low. For example, 1 year before the onset, the sensitivity is 68%, and two years before the onset, the sensitivity is 53%.

However, using other conventional clinical techniques such as B-ultrasound, CT, MRI, ERCP, PTCD, angiography, laparoscopy, etc., when the cancer is found, it is already in the middle and late stage of the cancer, which greatly delays the diagnosis and treatment.

Images